Fluticasone Furoate vs fluticasone furoate/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Fluticasone Furoate · Arnuity Ellipta
Marketed by GlaxoSmithKline
NCT00603382 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.
Reported efficacy
Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)
Result source: NCT00603278
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone Furoate | fluticasone furoate/vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT04651777 | —Trial running · NCT05757102 |
| Trough FEV1, change | 0.2 vs 0.0+0.1 vs placeboNCT0115991219 other results
| 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
|
| ACQ-5, change | —Trial running · NCT04651777 | -1.2 vs -1.1vs FFNCT032481281 other result
|
| OCS dose reduction | —Trial running · NCT04651777 | —Trial running · NCT05757102 |
Severe exacerbations, annualised rate
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
Trough FEV1, change
- Fluticasone Furoate
- 0.2 vs 0.0+0.1 vs placeboNCT01159912
19 other results
- 0.4 vs 0.2 NCT01165138
- 0.2 vs 0.0 NCT01436071
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- -0.1 vs -0.1 NCT02094937
- 0.4 vs 0.4 NCT01686633
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.1 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs 0.1 NCT01563029
- -0.5 vs -0.8 NCT01128569
- 0.1 vs 0.1 NCT01563029
- 0.3 vs 0.1 NCT01563029
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.3 vs 0.3 NCT01147848
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT03248128
- -0.1 vs -0.1 NCT02094937
- 0.3 vs 0.2 NCT03248128
ACQ-5, change
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
OCS dose reduction
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety
Coverage. Fluticasone Furoate: 23 of 23 rows · fluticasone furoate/vilanterol: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone Furoate Rows use multiple source trials | fluticasone furoate/vilanterol Rows use multiple source trials |
|---|---|---|
| ACT Control responder rate · % of participants | 99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| ACT Total absolute change · score | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| AQLQ Total absolute change · score | 0.84 vs 0.51 placebo score @ 24wk100 µg ODa,b NCT01159912 · Phase 3 1 other source trial0.93 vs 0.88 FF score @ 24wk200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 | 0.93 vs 0.88 FF score @ 24wk200/25 µg ODa,b NCT01134042 · Phase 3 · combination · Asthma · phase 3 |
| Evening PEF absolute change · L/min | 31.3 vs 9.6 placebo L/min200 µg ODc,d,a,b,e NCT00603382 · Phase 2 show 3 more doses25.7 vs 9.6 placebo L/min100 µg OD NCT00603382 · Phase 2 30.3 vs 9.6 placebo L/min50 µg OD NCT00603382 · Phase 2 23.6 vs 9.6 placebo L/min25 µg OD NCT00603382 · Phase 2 | 26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODd,a,b,e NCT01165138 · Phase 3 2 other source trials39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD NCT01686633 · Phase 3 41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD NCT01686633 · Phase 3 |
| Evening PEF absolute change · L | 24.9 vs 7.6 placebo L50 µg ODa,b,e NCT01436110 · Phase 3 · registry result, not featured evidence 1 other source trial22.8 vs 19.5 placebo L @ 12wk50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence | 39.2 vs -11.8 placebo L @ 12wk100/25 µg Once Dailya,b,e NCT01498679 · Phase 3 · registry result, not featured evidence 1 other source trial39.1 vs 10.5 Fluticasone Propionate L200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 |
| FEV1 absolute change · L | -0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODd,a,b,f NCT01128569 · Phase 2 · registry result, not featured evidence | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailyc,d,a,b,f NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence |
| FEV1 Trough absolute value · L | 2.83 vs 2.462 placebo L @ 12wk100/25 µg ODa,b NCT01165138 · Phase 3 | 2.83 vs 2.462 placebo L @ 12wk100/25 µg ODa,b NCT01165138 · Phase 3 |
| FEV1 Wm0 24 h absolute change · L | 0.464 vs 0.328 FF L @ 24wk200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 | 0.464 vs 0.328 FF L @ 24wk200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 |
| Morning PEF absolute change · L/min | 35.6 vs 13.6 placebo L/min200 µg ODc,d,g,b,e NCT00603382 · Phase 2 show 3 more doses29.5 vs 13.6 placebo L/min100 µg OD NCT00603382 · Phase 2 33.5 vs 13.6 placebo L/min50 µg OD NCT00603382 · Phase 2 27.2 vs 13.6 placebo L/min25 µg OD NCT00603382 · Phase 2 | 14.9 vs 9.3 FF L/min @ 12wkc,d,g,b,e NCT03248128 · Phase 3 · Asthma · phase 3 show 1 more dose11.9 vs 8.9 FF L/min @ 12wk NCT03248128 · Phase 3 · Asthma · phase 3 |
| Poorly-controlled Asthma Withdrawal responder rate · % of participants | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24 h Periods absolute change · percentage points | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24-h Period percent change · % of baseline | 32% (n=95) vs 21.9% (n=94) placebo200 µg ODc,d,a,b,e NCT00603382 · Phase 2 show 3 more doses40.8% (n=110) vs 21.9% (n=94) placebo100 µg OD NCT00603382 · Phase 2 34.5% (n=98) vs 21.9% (n=94) placebo50 µg OD NCT00603382 · Phase 2 29.3% (n=96) vs 21.9% (n=94) placebo25 µg OD NCT00603382 · Phase 2 | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailyd,a,b,e NCT02301975 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24-h Period absolute change · percentage points Rescue-free 24-hour periods | 38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD Rescue-free 24-hour periods NCT01134042 · Phase 3 · combination · Asthma · phase 3 | 38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD Rescue-free 24-hour periods NCT01134042 · Phase 3 · combination · Asthma · phase 3 |
| Severe Exacerbation Occurrence event count · % of participants | 15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk*100/25 µga,b NCT01086384 · Phase 3 · registry result, not featured evidence · converted to % from 154 participants as posted | 15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk*100/25 µga,b NCT01086384 · Phase 3 · converted to % from 154 participants as posted |
| Severe Exacerbation Rate Annualized event rate · Severe asthma exacerbations | 200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µga,b NCT01086384 · Phase 3 · registry result, not featured evidence | 200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µga,b NCT01086384 · Phase 3 |
| Symptom-free 24 h Periods absolute change · percentage points | -1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence 1 other source trial25.1% (n=116) vs 16.8% (n=114) placebo50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence | -1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24-h Period percent change · % of baseline | 31.7% (n=95) vs 18.4% (n=94) placebo200 µg ODc,d,a,b,e NCT00603382 · Phase 2 show 3 more doses38.7% (n=110) vs 18.4% (n=94) placebo100 µg OD NCT00603382 · Phase 2 31.1% (n=98) vs 18.4% (n=94) placebo50 µg OD NCT00603382 · Phase 2 25.3% (n=96) vs 18.4% (n=94) placebo25 µg OD NCT00603382 · Phase 2 | 32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg ODd,a,b,e NCT01165138 · Phase 3 3 other source trials27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD NCT01686633 · Phase 3 29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD NCT01686633 · Phase 3 24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24-h Period absolute change · percentage points Symptom-free 24-hour periods | 29.3% (n=197) vs 21% (n=193) FF @ 24wk200/25 µg OD Symptom-free 24-hour periods NCT01134042 · Phase 3 · combination · Asthma · phase 3 | 29.3% (n=197) vs 21% (n=193) FF @ 24wk200/25 µg OD Symptom-free 24-hour periods NCT01134042 · Phase 3 · combination · Asthma · phase 3 |
| Well Controlled Asthma responder rate · % of participants | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 9.5%200 µg ODh NCT00603382 · Phase 2 show 41 more results10.9%100 µg OD NCT00603382 · Phase 2 9%50 µg OD NCT00603382 · Phase 2 14.4%25 µg OD NCT00603382 · Phase 2 13.9%200 µg OD NCT00603278 · Phase 2 16.2%100 µg OD NCT00603278 · Phase 2 13.1%400 µg OD NCT00603278 · Phase 2 10.7%300 µg OD NCT00603278 · Phase 2 18.2%200 µg OD NCT00603746 · Phase 2 16.7%800 µg OD NCT00603746 · Phase 2 12.1%600 µg OD NCT00603746 · Phase 2 7.9%400 µg OD NCT00603746 · Phase 2 19.3%100 µg OD NCT01159912 · Phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 12.6%200 µg OD NCT01431950 · Phase 3 16%100 µg OD NCT01431950 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 28%100 µg OD NCT01563029 · Phase 2 27.5%50 µg OD NCT01563029 · Phase 2 20.3%25 µg OD NCT01563029 · Phase 2 13.9%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 7.2%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 9.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 22.2%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 11.3%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.8%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 3.6%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | —100/25 µgi NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.1%200 µg ODh NCT00603382 · Phase 2 show 41 more results1.8%100 µg OD NCT00603382 · Phase 2 1%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 1%200 µg OD NCT00603278 · Phase 2 2.9%100 µg OD NCT00603278 · Phase 2 2%400 µg OD NCT00603278 · Phase 2 0%300 µg OD NCT00603278 · Phase 2 3%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 1.8%100 µg OD NCT01159912 · Phase 3 1%100/25 µg OD NCT01165138 · Phase 3 1.7%200 µg OD NCT01431950 · Phase 3 1.7%100 µg OD NCT01431950 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1.7%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 —50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.9%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | —100/25 µgi NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%200 µg ODh NCT00603382 · Phase 2 show 41 more results0.9%100 µg OD NCT00603382 · Phase 2 0%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 0%200 µg OD NCT00603278 · Phase 2 0%100 µg OD NCT00603278 · Phase 2 1%400 µg OD NCT00603278 · Phase 2 1%300 µg OD NCT00603278 · Phase 2 2%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 3.5%100 µg OD NCT01159912 · Phase 3 0%100/25 µg OD NCT01165138 · Phase 3 3.4%200 µg OD NCT01431950 · Phase 3 2.5%100 µg OD NCT01431950 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 0.8%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 2.5%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy 0% NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.3%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 1.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0.8%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence 4.1%100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence 0.5%200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.5%100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%100 µg NCT01332292 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence 0%200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence 0%100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | 4.1%100/25 µgi NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 µg ODh headache 5.3% (placebo 10.6%) nasopharyngitis 3.2% (placebo 1.1%) oropharyngitis 3.2% (placebo 1.1%) NCT00603382 · Phase 2 show 40 more results100 µg OD headache 10.9% (placebo 10.6%) nasopharyngitis 3.6% (placebo 1.1%) oropharyngitis 3.6% (placebo 1.1%) NCT00603382 · Phase 2 50 µg OD headache 6% (placebo 10.6%) back pain 3% (placebo 0%) oropharyngitis 1% (placebo 1.1%) NCT00603382 · Phase 2 25 µg OD headache 6.2% (placebo 10.6%) back pain 0% (placebo 0%) nasopharyngitis 0% (placebo 1.1%) NCT00603382 · Phase 2 200 µg OD headache 7.9% (placebo 5.6%) nasopharyngitis 5% (placebo 7.5%) upper respiratory tract infection 3% (placebo 2.8%) NCT00603278 · Phase 2 100 µg OD headache 8.6% (placebo 5.6%) nasopharyngitis 8.6% (placebo 7.5%) diarrhoea 3.8% (placebo 0%) NCT00603278 · Phase 2 400 µg OD headache 9.1% (placebo 5.6%) cough 4% (placebo 0.9%) nasopharyngitis 4% (placebo 7.5%) NCT00603278 · Phase 2 300 µg OD headache 7.8% (placebo 5.6%) nasopharyngitis 6.8% (placebo 7.5%) back pain 2.9% (placebo 0%) NCT00603278 · Phase 2 200 µg OD dysphonia 4% (placebo 1%) oropharyngeal candidiasis 4% (placebo 1%) headache 3% (placebo 9.7%) NCT00603746 · Phase 2 800 µg OD headache 9.8% (placebo 9.7%) nasopharyngitis 6.9% (placebo 3.9%) oral candidiasis 6.9% (placebo 0%) NCT00603746 · Phase 2 600 µg OD headache 11.2% (placebo 9.7%) back pain 3.7% (placebo 1%) pharyngolaryngeal pain 2.8% (placebo 1%) NCT00603746 · Phase 2 400 µg OD headache 9.9% (placebo 9.7%) dysphonia 5% (placebo 1%) nasopharyngitis 5% (placebo 3.9%) NCT00603746 · Phase 2 100 µg OD nasopharyngitis 7.9% (placebo 5.2%) bronchitis 7% (placebo 6.1%) headache 6.1% (placebo 4.3%) NCT01159912 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 50 mcg upper respiratory tract infection 12.2% (placebo 13.8%) nasopharyngitis 9.7% (placebo 10.5%) rhinitis 6.7% (placebo 7.5%) NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 · registry result, not featured evidence 50 µg OD headache 14.5% (placebo 11.3%) nasopharyngitis 6.8% (placebo 5.2%) pharyngitis 6% (placebo 8.7%) NCT01436110 · Phase 3 · registry result, not featured evidence 50 µg OD nasopharyngitis 5.8% (placebo 4.1%) headache 5% (placebo 11.6%) pharyngitis 5% (placebo 5%) NCT01436071 · Phase 3 · registry result, not featured evidence 100/25 µg headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 · registry result, not featured evidence 200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 · registry result, not featured evidence 200/25 µg PM headache 16.1% (placebo 8.6%) back pain 3.6% (placebo 0%) sinus headache 3.6% (placebo 0%) NCT01086410 · Phase 3 · registry result, not featured evidence 100/25 µg PM headache 26.8% (placebo 8.6%) arthralgia 3.6% (placebo 0%) nasopharyngitis 3.6% (placebo 1.7%) NCT01086410 · Phase 3 · registry result, not featured evidence 100 µg AM headache 52.2% (placebo 36%) upper respiratory tract infection 26.1% (placebo 8%) nasopharyngitis 8.7% (placebo 4%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg PM headache 41.7% (placebo 36%) viral upper respiratory tract infection 20.8% (placebo 8%) dysmenorrhoea 8.3% (placebo 8%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 100 µg headache 11.5% (placebo 0%) acute tonsillitis 3.8% (placebo 0%) cough 3.8% (placebo 0%) NCT01332292 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence 200 µg OD upper respiratory tract infection 5% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence 100 µg BID upper respiratory tract infection 4.9% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence | 100/25 µgi headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 2 versus Phase 3.
- eThe assessment timepoint is not available for both results.
- fAssessment timepoints differ: 4.14 weeks versus 24 weeks.
- gPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- hPopulation comparability has not been reviewed for 41 of these studies.
- iPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone Furoate
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 11 further endpoints in the CSV export.
fluticasone furoate/vilanterol
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone Furoate's landscape · fluticasone furoate/vilanterol's landscape